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Background: High iron load might have a number of toxic effects in the organism. Recently intravenous (iv) iron has
been proposed to induce elevation of fibroblast growth factor 23 (FGF23), hypophosphatemia and osteomalacia in iron
deficient subjects. High levels of FGF23 are associated with increased mortality in the chronic kidney disease (CKD)
population. CKD patients are often treated with iv iron therapy in order to maintain iron stores and erythropoietin
responsiveness, also in the case of not being iron depleted. Therefore, the effect of a single high iv dose of two
different iron preparations, iron isomaltoside 1000 (IIM) and ferric carboxymaltose (FCM), on plasma levels of FGF23
and phosphate was examined in normal and uremic iron repleted rats.
Methods: Iron was administered iv as a single high dose of 80 mg/kg bodyweight and the effects on plasma levels of
iFGF23, phosphate, Ca2+, PTH, transferrin, ferritin and iron were examined in short and long term experiments (n = 99).
Blood samples were obtained at time 0, 30, 60, 180 minutes, 24 and 48 hours and in a separate study after 1 week.
Uremia was induced by 5/6-nephrectomy.
Results: Nephrectomized rats had significant uremia, hyperparathyroidism and elevated FGF23. Iron administration
resulted in significant increases in plasma ferritin levels. No significant differences were seen in plasma levels of iFGF23,
phosphate and PTH between the experimental groups at any time point within 48 hours or at 1 week after infusion of
the iron compounds compared to vehicle.
Conclusions: In non-iron depleted normal and uremic rats a single high dose of either of two intravenous iron
preparations, iron isomaltoside 1000, and ferric carboxymaltose, had no effect on plasma levels of iFGF23 and
phosphate for up to seven days.
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Intravenous (iv) iron supplementation is an integrated
part of the management of anemia in patients with
chronic kidney disease (CKD). Treatment of anemia in
CKD requires in many instances erythropoietin (EPO).
To ensure that full benefit from EPO is obtained most
patients require iron supplement during the treatment,
even when they are not iron depleted [1]. Intravenous
iron administration has been shown to reduce the need
for EPO and to make anemia treatment more cost effective
[2-4]. However, excessive iron load is potentially harmful.
Evidence from experimental studies have shown that iron
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stated.neutrophil activity, enhance oxygen radical generation,
promote arteriosclerosis and increase mortality [5-8].
Recently a link between fibroblast growth factor 23
(FGF23) and iron homeostasis has been proposed
[9-14], potentially adding a further negative effect to
those reported from iv administration of iron [5-8,15].
During recent years the bone derived phosphaturic
hormone, FGF23 and its co-receptor, Klotho, have been
extensively studied and their role in phosphate homeo-
stasis is now well established, although many questions
regarding the regulation of FGF23 and Klotho still remain
unanswered [16]. It is well documented that disturbed
phosphate metabolism plays a critical role in the patho-
physiology of uremia and that hyperphosphatemia is an
important factor in the development of vascular calcifi-
cation in CKD [17]. Plasma FGF23 increases very earlyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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diovascular mortality. In dialysis patients FGF23 levels
are extremely elevated. FGF23 itself has been shown to
mediate off-target direct end-organ toxicity in the heart
promoting cardiomyocyte hypertrophy. Elevated FGF23
may represent a specific factor in the adverse cardiovascular
outcome and is not only a parameter of disturbed phos-
phate homeostasis in CKD [18-21]. A further iron-triggered
augmentation of the already increased FGF23 levels in
CKD patients might as such theoretically contribute to
the potential negative effects of FGF23 on mortality [20].
In non-CKD patients iv iron was shown to induce
increased FGF23 secretion [13,14]. Recent data suggest
that iron deficiency may stimulate FGF23 transcription
[19,22,23]. A more recent study by Wolf et al. [11]
compared the effect of a single dose of ferric carboxy-
maltose (FCM) or iron dextran on intact FGF23 (iFGF23)
and C-terminal FGF23 (cFGF23) levels in iron-deficient,
anemic women with normal kidney function. In accord-
ance with prior reported results they found that iron
deficiency was associated with markedly increased cFGF23
levels. After administration of both FCM and iron dextran
cFGF23 fell significantly, while a transient increase in
iFGF23 levels was observed within the first 24 hours in
the FCM group [11]. This underlines the importance of
designing studies on iron effects/toxicity with the inclusion
of several measurements, as the plasma concentrations of
the biologically active compound, iFGF23, and its inactive
fragment, cFGF23 might fluctuate and respond differently.
In the same study the authors proposed the possibility that
induction of non-skeletal sources of FGF23 by iron treat-
ment in iron deficient subjects may theoretically take place.
The complex relationship between iron status and FGF23
regulation might potentially reflect both disturbed bone
remodeling in iron deficiency [24], disturbed iron sensing
and signaling and adaptive responses to iron deficiency
[25]. It is therefore of importance to investigate the effect
of iv iron not only in iron depleted subjects, but also in
normal condition.
In CKD, Takeda et al. examined the effects of iv iron on
iFGF23 in hemodialysis patients [12] and found a signifi-
cant increase in iFGF23 after 40 mg of saccharated iron
three times weekly over three months. This was not
accompanied by hypophosphatemia due to absence of
kidney function, while a significant, but transient decrease
in plasma PTH was demonstrated, further stressing
the importance of also examining the effect of iv iron
on other parameters of mineral homeostasis, even though
focus of the study mainly is on the relationship between
iron and FGF23. The susceptibility to iron mediated
toxicity can differ between normal and CKD conditions,
as previously demonstrated [5] and demands for exami-
nations not only at normal GFR, but also in models
of CKD.The recent evidence for an effect of iv iron on the
rise of FGF23 levels is generated from studies on iron
depleted subjects [11,13,14,22,23,26]. However, iv iron
treatment in the CKD population is also often routinely
provided to iron repleted individuals in order to maintain
iron stores and EPO responsiveness, and as such it is
of importance to study whether iv iron administration
influences FGF23 and mineral homeostasis in the iron
repleted condition.
The aim of the present study therefore was in non-iron
deficient normal and uremic rats to examine the short and
long-term effects of a single high intravenous dose of two
different iron preparations, iron isomaltoside 1000 (IIM)
and ferric carboxymaltose (FCM) on plasma FGF23 levels
and other parameters of the mineral homeostasis.
Methods
Animals
Adult male Wistar rats, 250 g (Taconic A/S, Ejby, Denmark)
were housed in a temperature-controlled environment
with a 12-hour light/dark circle with free access to food
and water. The experimental studies were performed in
accordance with Danish law and approved by the Animal
Experiments Inspectorate, the Ministry of Food, Agriculture
and Fisheries, Denmark.
Uremia
Chronic renal failure (CRF) was induced by one-step 5/6
nephrectomy, as previously described [27]. Rats were
anaesthetized with hypnorm/midazolam (Panum Institute,
Copenhagen, Denmark), and were given carprofen (Rimadyl,
Pfizer, Copenhagen, Denmark) subcutaneously as pain
relief for the following three days. CRF rats (n = 54) were
fed a high phosphorus diet containing 1.4% phosphorus,
0.9% calcium, per kg (Altromin, Spezialfutter GmbH &
Co., KG, Germany) in order to induce severe uremia and
hyperparathyroidism. Duration of uremia was 8 weeks.
Normal rats (n = 45) were fed a standard diet containing
0.9% calcium, 0.7% phosphorus, 165 mg iron and 600 IU
vitamin D per kg diet (Altromin, Germany).
Iron preparations and administration
Iron isomaltoside 1000 (IIM) (Monofer, Pharmacosmos,
Holbaek, Denmark) is a chemical modification of isomalto-
oligosaccharides that consists predominantly of 3–5 non-
branched glucose units which bind iron within the matrix.
Ferric carboxymaltose (FCM) (Ferinject, Vifor Pharma,
Glattbrug, Switzerland) contains iron in a stable ferric
state as a complex with a carbohydrate polymer. The
dose of the two iron preparations given in this trial was
80 mg/kg body weight. The maximal recommended
single dose in humans of IIM is 20 mg/kg body weight
and a total of 1000 mg for FCM. The iron was given
intravenously as a single dose of either IIM or FCM.
Table 1 Baseline plasma biochemistry
Plasma parameters Normal rats Uremic rats
n 45 54
FGF23, pg/mL 118 ± 10 1624 ± 136***
PTH, pg/mL 59 ± 11 1592 ± 194***
Ferritin, ng/mL 423 ± 78 698 ± 87*
Iron, μmol/L 16.3 ± 2.5 26.6 ± 4.0*
Transferrin, g/L 1.6 ± 0.1 1.4 ± 0.1
Creatinine, μmol/L 25.8 ± 0.5 76.9 ± 3.9***
Urea, mmol/L 7.6 ± 0.2 22.4 ± 0.9***
Ca2+, mmol/L 1.37 ± 0.01 1.09 ± 0.02***
P, mmol/L 1.80 ± 0.06 2.88 ± 0.11***
K, mmol/L 5.0 ± 0.1 5.4 ± 0.1**
Na, mmol/L 141 ± 0.2 141 ± 0.4
Data are mean ± SEM. *P < 0.05; **P < 0.001; ***P < 0.0001 vs normal rats.
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sodium chloride in a total volume of 1 ml. The vehicle
group received 1 mL of sodium chloride. IIM, FCM or
vehicle was injected into the femoral vein after free
dissection under stereomicroscope.
Design
The studies were performed both as a short-term (48 hour)
intensive study and a long- term (1 week) study to assess
the effects of a single intravenous injection of IIM or FCM
on plasma FGF23 and other biochemical parameters in
normal and uremic rats.
In the 48-hour studies blood samples were obtained at
baseline and 30, 60, 120 and 180 minutes and again after
24 and 48 hour. In the 1-week studies blood samples were
obtained at baseline and after 1 week. The following ex-
perimental groups were examined, using a total of 99 rats:
Group 1: Normal rats, (48 hours) given vehicle (n = 9)
Group 2: Normal rats, (48 hours) given IIM (n = 8)
Group 3: Normal rats, (48 hours) given FCM (n = 9)
Group 4: Uremic rats, (48 hours) given vehicle (n = 11)
Group 5: Uremic rats, (48 hours) given IIM (n = 10)
Group 6: Uremic rats, (48 hours) given FCM (n = 14)
Group 7: Normal rats, (1 week) given vehicle (n = 6)
Group 8: Normal rats, (1 week) given IIM (n = 7)
Group 9: Normal rats, (1 week) given FCM (n = 6)
Group 10: Uremic rats, (1 week) given vehicle (n = 6)
Group 11: Uremic rats, (1 week) given IIM (n = 7)
Group 12: Uremic rats, (1 week) given FCM (n = 6)
As we observed that plasma levels of cFGF23 increased
during the short-term experimental conditions, we decided
to examine the performance of C-terminal and intact
FGF23 without any intervention and further to examine
the potential effect of two different anesthetics on
cFGF23 levels. Blood samples were obtained at 0, 60
and 120 minutes in:
Group 13: Normal rats, no sedation (n = 4)
Group 14: Normal rats, given pentobarbital
anesthesia (n = 4)
Group 15: Normal rats, given hypnorm/midazolam
anesthesia (n = 4)
Biochemistry
Plasma iFGF23 was measured by an intact FGF23 ELISA
assay (Kainos Laboratories, Tokyo, Japan), intra-assay
coefficient of variation of 2.5% and inter-assay coefficient of
variation of 5% in our lab. Plasma cFGF23 was measured
by a C-terminal FGF23 ELISA assay (Immutopics, San
Clemente, CA, USA) intra-assay coefficient of variation
of 5.4% and inter-assay coefficient of variation of 5.2%.
Plasma PTH was measured by a rat bioactive intact PTHELISA assay (Immunotopics, San Clemente, CA, USA)
with an intra- assay variation of 4% and inter-assay vari-
ation of 9% [28]. Plasma ferritin and plasma transferrin
were both measured by ELISA assays (Alpco, Salem, New
Hampshire, USA). Plasma phosphate, urea and creatinine
were analyzed by Vitros 250 (Ortho-Clinical Diagnostics,
Raritan, NJ, USA). Plasma Ca2+, K+, and Na + by ABL 505
(Radiometer, Copenhagen, Denmark). Plasma iron was
measured at Department of Biochemistry, Rigshospitalet,
Copenhagen, DK.Statistics
All data are presented as mean ± SEM. Differences between
multiple groups were analyzed using one-way ANOVA
followed by Bonferroni’s post hoc test. When comparing
multiple groups at different time points two-way ANOVA
was used. Two-sided t-test was used when comparing only
two groups with normal distribution. P < 0.05 was consid-
ered statistically significant. The analyses were performed
using Graph Pad Prism version 4.Results
Induction of uremia and iron administration
Uremia and severe secondary hyperparathyroidism were
successfully induced by 5/6- nephrectomy and high-
phosphate diet, Table 1. Uremic animals had significantly
elevated levels of plasma creatinine, urea and iFGF23 as
well as significantly elevated plasma phosphate and PTH
as compared to normal rats (p < 0.0001). Basal plasma
ferritin and iron levels were higher in the uremic group
(p < 0.05).
Administration of iron had no effect on plasma creatin-
ine and urea at any time point (data not shown). Some
mortality was observed within hours after intravenous iron
(3 in the IIM group and 3 in the FCM group in the normal
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rat died after vehicle injection.
Effect of intravenous iron administration on iron
parameters in normal and uremic rats
Iron administration was confirmed by significant increases
in plasma ferritin levels. Thus, at 48 hours both normal
and uremic IIM and FCM treated groups had significantly
increased plasma ferritin vs vehicle groups (p < 0.001)
(Figure 1). No differences were seen in plasma ferritin
when comparing IIM and FCM groups in both normal
and uremic rats. No change was seen in plasma iron in
either normal or uremic rats at 48 hours. In normal
rats a slight decrease was seen in plasma transferrin in
the IIM group vs the vehicle group (p < 0.05), whereas
no change was seen in the FCM group. In the uremic
rats no change was seen in plasma transferrin levels.
At 1 week the plasma ferritin increased significantly in
both normal and uremic IIM and FCM treated groups
as compared to vehicle group (p < 0.01), and further the
plasma ferritin was higher in the normal IIM group when
compared to the normal FCM group (Figure 1, p < 0.05).
Effect of intravenous iron administration on plasma PTH
The uremic rats had significantly elevated plasma PTH
levels as compared to normal rats (Table 1). No significant
changes were seen in plasma PTH levels after intravenous
iron or vehicle in any of the groups. In normal rats in the
48 hour study, PTH levels in the vehicle group were
110 ± 38 at baseline vs 82 ± 32 pg/mL at 48 hours, in the
IIM group 47 ± 15 vs 60 ± 35 pg/mL, and in the FCM
group 82 ± 39 vs 60 ± 23 pg/mL. In the 1 week study
plasma PTH in the vehicle group was 18 ± 2 at baseline vsFigure 1 Plasma ferritin, transferrin and iron levels in normal and ure
vehicle, iron isomaltoside (IIM) or ferric carboxymaltose (FCM). The iro
both normal and uremic rats receiving IIM and FCM. Mean ± SEM. *p < 0.05 vs16 ± 2 pg/mL at 1 week, in the IIM group 30 ± 7 vs 21 ±
3 pg/mL, and in the FCM group 40 ± 14 vs 26 ± 6 pg/mL.
Similarly, in uremic rats no significant changes in
plasma PTH were observed: In the 48 hour study,
plasma PTH in the vehicle group was 1452 ± 516 at
baseline vs 1567 ± 664 pg/mL at 48 hours; in the IIM
group 297 ± 81 vs 645 ± 344 pg/mL; and in the FCM
group 466 ± 161 vs 911 ± 326 pg/mL. Plasma PTH in the
1 week study of uremic rats was stable; in the vehicle
group 2477 ± 388 at baseline vs 2596 ± 464 pg/mL at 1
week; in the IIM group 2609 ± 282 vs 2391 ± 400 pg/mL;
and in the FCM group 2243 ± 264 vs 1884 ± 344 pg/mL.
Plasma Ca2+ was measured at all intermediate time points
and remained stable within 48 hours and 1 week in both
normal and uremic rats (data not shown).
Effect of intravenous iron administration on iFGF23 and
plasma phosphate in normal and uremic rats
Plasma iFGF23 and phosphate were measured at several
time points within 48 hours after intravenous iron
administration in normal rats and at baseline and 48
hours in uremic rats. No significant differences were
found between vehicle, IIM or FCM-groups at any time
in neither normal nor uremic rats. Significant variations
in both plasma phosphate and iFGF23 were however
observed within the single group during the experiments.
In the groups of normal rats plasma iFGF23 and phos-
phate increased, but inconsistently within 48 hours and at
different time points (Figure 2). In the uremic rats both
plasma phosphate and iFGF23 levels were significantly
elevated as compared to the normal groups (Table 1,
p < 0.001). No significant differences were found between
the vehicle group and the two iron groups in plasmamic rats at 48 hours and 1 week after a single injection of either
n load was confirmed by significant increases of plasma ferritin levels in
vehicle, **p < 0.01 vs vehicle, ***p < 0.001 vs vehicle, αp < 0.05 vs FCM.
Figure 2 Plasma phosphate and intact FGF23 in normal and uremic rats at 48 hours (a + b) and 1 week (c + d) after vehicle or a single
high dose of intravenous iron isomaltoside (IIM) or ferric carboxymaltose (FCM). Compared to vehicle, intravenpous iron had no significant
effect on plasma phosphate and iFGF23 levels in normal and uremic rats, neither within the first 48 hours nor 1 week after the injection. Within
the single group some significant variations in both phosphate and iFGF23 levels were observed, but not different from what was observed in
the vehicle group. Mean ± SEM. *p < 0.05 vs 0 minutes, **p < 0.01 vs 0 minutes within the groups.
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a slight decrease was seen in both phosphate and iFGF23
levels with no difference between the groups (Figure 2
a + b). In a subgroup of uremic rats measurements were
performed at intermediate time points as well, again with
no differences between the vehicle group and the two iron
groups at any time (data not shown).
As no significant differences in iFGF23 levels were
observed at any time between the groups within 48
hours, six additional groups of normal and uremic rats
had similar doses of iron or vehicle injected and were
followed for 1 week. In the 1-week study no change was
seen in plasma phosphate levels (Figure 2 c + d). iFGF23
levels in normal rats increased significantly (p < 0.05) in
the two iron treated groups, as compared to their baseline;
this increase was however not significantly different from
that of the control group, and as such no difference in
response was seen between the 3 groups. In the uremic
rats no significant changes were seen in neither plasma
phosphate nor iFGF23 after 1 week.
The stability of intact FGF23 in contrast to C-terminal
FGF23 during short-term experimental conditions
The plasma levels of cFGF23 were examined by repeated
measurements in three groups of normal rats, one wit-
out anesthesia, and two groups anesthetized either withpentobarbital or hypnorm/midazolam, but still without
any other intervention. Already after 1 hour did the
levels of cFGF23 increase significantly (p < 0.05), and
remained elevated after 2 hours (p < 0.01). This increase
was seen in both non-anesthetized and anesthetized
rats and was similar for the two different anesthetics
used. The levels of iFGF23 were in contrast to cFGF23
levels, stable during the first 2 hours of experimental
time (Figure 3). Therefore, only iFGF23 was chosen to
be measured in the present study.
Discussion
This is the first study to examine the effect of intravenous
iron on plasma iFGF23 levels in non-iron depleted rats.
The effect of a single high dose of two different iron
preparations intravenously, iron isomaltoside 1000, and
ferric carboxymaltose, as compared to that of saline was
examined. The dose of the two iron preparations given in
this trial was 80 mg/kg body weight. For comparison, the
maximal recommended single dose in humans of IIM is
20 mg/kg body weight and a total of 1000 mg for FCM.
The biological effectiveness was ensured by significantly
elevated plasma ferritin levels. No effect of very high doses
of iv iron was found on iFGF23 neither in normal rats
nor in uremic rats in both short-term (two days) and
long-term (one week) studies.
Figure 3 Stability of plasma intact FGF23 levels as compared to increasing C-terminal FGF23 during short term experimental conditions.
Monitoring of iFGF23 resulted in stable levels, while levels of cFGF23 increased significantly already within 1 hour (p < 0.05), and remained
elevated for 2 hours (p < 0.01). This increase of cFGF23 was seen both in non-anesthetized, awake rats and anesthetized rats and was similar for
the two different anesthetics used. The rats were not subject to further intervention. Mean ± SEM. *p < 0.05 vs 0 min, **p < 0.01 vs 0 min.
Gravesen et al. BMC Nephrology 2013, 14:281 Page 6 of 8
http://www.biomedcentral.com/1471-2369/14/281Experimental uremia was associated with severely dis-
turbed mineral homeostasis, with significant hyperpara-
thyroidism, hyperphosphatemia, hypocalcemia and very
high levels of FGF23. Previously, it has been shown that
the increased levels of FGF23 in uremia depend upon
the degree of secondary hyperparathyroidism [29] and
that a feed-back mechanism probably exists with FGF23
also having a regulatory effect on parathyroid function
[30]. Intravenous iron administration did in the present
investigation not result in a further increase of FGF23 and
did not induce changes in plasma PTH, phosphate or
Ca2+ levels. Blood samles were obtained at close intervals
and as such, even a staggered response to iv iron of some
of the parameters involved in the integrated regulation
between FGF23 and PTH should have been detected.
Studies on genetic hypophosphatemic disorders indicate
the existence of a robust link between iron deficiency
and FGF23, although the exact regulatory mechanism is
not known. It was in the hypophosphatemic disorders,
autosomal dominant hypophosphatemic rickets (ADHR)
and tumor induced osteomalacia (TIO), that FGF23 first
was identified and its role in phosphate metabolism recog-
nized [31,32]. ADHR, TIO, X-linked hypophosphatemic
rickets (XLH) and autosomal recessive hypophosphatemic
rickets (ARHR) are all characterized by excess of iFGF23
[33]. These disorders show similar phenotypes character-
ized by hypophosphatemia, low 1,25(OH)2D levels and
osteomalacia, but unlike XLH and ARHR, ADHR shows
incomplete penetrance and variable age of onset. In
ADHR, FGF23 is resistant to proteolytic cleavage due
to mutations in the area of the cleavage site, separating
the N-terminal from the C-terminal part [31]. Studies
of families with ADHR have led to the observation that
the onset of disease in ADHR-subjects can occur
during physiological states of iron-deficiency [34]. Theseobservations, linking iron status to FGF23, have later
been supported by studies in ADHR knock-in mouse,
where iron deficiency was sufficient to cause the ADHR
phenotype [22].
Previous observations suggested that administration of
parenteral iron might be associated with hypophosphate-
mia and osteomalacia [14,26]. Schouten et al. therefore
examined the effect of a single infusion of iron polymal-
tose in non-CKD patients suffering from iron deficiency,
and found a significant and prolonged increase in iFGF23
levels, which was accompanied by a decrease in plasma
phosphate, increased phosphate excretion and suppressed
1,25(OH)2D [13]. The mechanisms underlying these changes
are still speculative, although it has been suggested that
iron might be involved in the regulation of the rate of
enzymatic cleavage of iFGF23, putting forward the idea,
that increased iron levels inhibit and iron deficiency
increases protease activity which would fit with the
findings of elevated cFGF23 fragments in patients with
low plasma ferritin. In the present study, however, no
increase in iFGF23 was observed and no changes in
plasma phosphate levels were induced by any of the
two iron compounds given intravenously neither in
short-term nor in long-term investigations.
The results of the present investigation are interesting
in relation to some recently published results in human
subjects, where a single dose of ferricarboxymaltose (FCM)
corresponded with an increase in iFGF23 after two days
and one week and resulted in increased fractional excretion
of phosphate and decreased plasma phosphate, while iron
dextran in the same study did not affect iFGF23 levels
[11]. A main difference to our study, beside the obvious
difference in species, is that the human subjects were
severely iron depleted [11], while the rats in the present
study not were iron deficient.
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the effect of a single iv iron dose on FGF23 and phosphate
levels and reported varying results. Two studies found an
increase of plasma iFGF23 within the first week after iv
iron [10,13], while one study, examining saccharated ferric
oxide, found unchanged iFGF23 levels during the first
week and then a rise after three weeks of repeated weekly
administration [12]. In another study, using a cFGF23 assay
and a single dose of FCM in 47 non-dialysis CKD patients
with iron deficiency it was found that both plasma phos-
phate and cFGF23 were reduced for up to 12 weeks [9].
It should be stressed that all these human studies were
performed in iron-deficient subjects and that the physio-
logical response to iron load could differ according to
baseline iron status. Our purpose was however to examine
the effect of intravenous iron in iron repleted conditions
and doing so no effect on iFGF23 was found and the
phosphate levels were stable. In a study relating iron
levels with iFGF23 and cFGF23 in both ADHR and
healthy subjects Imel et al. found that the iron-levels in
ADHR subjects were negatively correlated to both
iFGF23 and cFGF23. In healthy subjects they found no
correlation between iron levels and iFGF23, while a
negative correlation to cFGF23 made them hypothesize,
that iron deficiency might cause increased expression
of FGF23, which in healthy subjects is counter regulated
by an increased cleavage [23].
When iv iron is administered, the iron-carbohydrate
agents enter the reticuloendothelial system (RES). Then
iron is subsequently released, and either bound to intra-
cellular ferritin or transferrin in the blood. The rate of
uptake into RES depends on the particle size, with small
molecules being taken up rapidly. Only a small fraction
of iron is directly transferred to transferrin from the
iron-carbohydrate particle. The release of iron from the
RES is dependent on iron-status. In anemic, iron-deficient
individuals iron is rapidly released from the RES and it
has been reported that all iron is incorporated into
erythrocytes within 2–4 weeks in severely anemic, iron
deficient individuals [35]. Furthermore, also the carbo-
hydrate part of the iron agents could interfere with
FGF23 synthesis and degradation [11], and as such,
apparently contradictory results could be due to the
use of different iron agents.
The mechanism behind the effect of iv iron on both
iFGF23 and cFGF23 is still unresolved. In normal rats,
without any intervention, the cFGF23 levels turned out
to be significantly increasing within a brief experimental
time period of 120 minutes. This was in contrast to
levels of iFGF23, which remained stable. The behavior of
cFGF23 did not depend upon the use of anesthetics. As
such, we concluded that in this experimental rat model
measurements of cFGF23 were not suitable for studying
the rapid regulation of FGF23. In the present studytherefore only the biologically active iFGF23 was measured.
Thus, an eventual effect of iron on the metabolism of
FGF23 was not studied, although such a possibility recently
has been proposed [13]. Whether the observed increase in
cFGF23 might be due to a diurnal variation [36-39] must
await future studies.
An apparent rise in iFGF23 levels was seen normal rats
after 48 hours and 1 week in both the two iron groups
as well as in the vehicle group, but with no significant
differences between the three groups, indicating that this
rise was not caused by the iron administration. iFGF23
levels did not increase in any of the uremic groups. These
results underline the importance of including an appropri-
ate control group, when evaluating FGF23 levels.
Conclusion
In conclusion, a single intravenous high dose of either iron
isomaltoside 1000 or ferric carboxymaltose had no signifi-
cant effect on intact FGF23 plasma levels for up to 7 days
in non-iron deficient normal and uremic rats.
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